LOGIN
ID
PW
MemberShip
2023-12-07 11:56
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Policy
Bioequivalence reevals speed up in line with drug price reev
by
Lee, Hye-Kyung
Sep 21, 2023 05:24am
With the number of items requiring equivalence tests expanded as such, the Ministry of Food and Drug Safety is also accelerating the reevaluation of those that were previously approved. In particular, it is said that the review is being further accelerated this year as its timing overlaps with the reevaluation of the insurance price ceiling amou
Policy
Pseudoephedrine price negotiations have been concluded
by
Lee, Tak-Sun
Sep 21, 2023 05:24am
Quick agreement reached after a week of negotiations, likely to be implemented in October It appears that the single agent for colds, Pseudoephedrine, will be subject to increased drug prices starting in October. There is news that drug price adjustment negotiations with the NHIS, which have been ongoing since last week, have been concluded
Policy
¡®Introduce a Korean Cancer Moonshot Plan for patients'
by
Lee, Jeong-Hwan
Sep 21, 2023 05:24am
It has been pointed out that Korea also needs a policy that can improve the quality of life of cancer patients by providing reasonable compensation for cancer treatment technologies such as robot-assisted surgery and advanced radiation therapy to improve the quality of life of cancer patients in Korea, like in the case of the U.S. Cancer Mo
Policy
Generics for Janumet competition begins in earnest in Oct.
by
Lee, Tak-Sun
Sep 21, 2023 05:23am
The diabetes treatment market is expected to remain active in October. This is because salt-modifying complex drugs that were not registered in September are hitting the market all at once. According to the industry on the 20th, generics of MSD's DPP-4 inhibitory diabetes combination drug 'Janumet and Janumet XR' will be listed in large numb
Policy
High-priced drugs need adjustment from the approval stage
by
Lee, Tak-Sun
Sep 20, 2023 05:36am
He also explained that he would conduct a pilot project to curb multi-drug prescriptions to reduce usage. Chairman Jeong made this announcement at a press conference for a health magazine held at a restaurant in Gwanghwamun, Seoul on the 15th. He said, ¡°It is true that as income increases, prescriptions switch to more expensive drugs even i
Policy
The NHIS begins negotiations to increase the size of PSE
by
Lee, Tak-Sun
Sep 20, 2023 05:36am
The NHIS has started negotiations to adjust the drug price increase for the ingredient formulation of the nose cold medicine Pseudoephedrine (PSE), which is struggling with supply and demand. The deadline for this negotiation is 60 days, but it is said to be targeting an agreement this month. If this month's negotiations are signed, it is h
Policy
Reimbursement imminent for some anticancer drugs in KOR
by
Lee, Tak-Sun
Sep 20, 2023 05:35am
Jeperli Inj (dostarlimab, GSK) and Braftovi Cap 75mg (encorafenib, Ono), which passed the Drug Reimbursement Evaluation Committee meeting last month, are currently in drug price negotiations with the National Health Insurance Service. According to industry sources on the 19th, the National Health Insurance Service recently updated the li
Policy
MFDS starts review on phenylephrine after FDA advisory decis
by
Lee, Hye-Kyung
Sep 19, 2023 05:42am
With the Nonprescription Drug Advisory Committee (NDAC) concluding that the nasal decongestant ¡®phenylephrine¡¯ is not effective, Korea¡¯s Ministry of Food and Drug Safety is also preparing to conduct its review. An MFDS official said, ¡°We will decide on future measures after a comprehensive review, including discussion with experts,
Policy
Januvia generics up for insurance price cuts¡¦ 119 combinati
by
Lee, Tak-Sun
Sep 19, 2023 05:41am
Caution is required for the use of the generic versions CPP-4 inhibitor class antidiabetic drug ¡®Januvia (sitagliptin, MSD)¡¯ that have poured out into the Korean market as many are subject to price cuts due to inequality of price when they are prescribed in multiplications. According to industry sources on the 18th, HIRA recently added
Policy
Olumiant re-examination period extended by 35 months
by
Lee, Hye-Kyung
Sep 18, 2023 05:26am
In March of this year, the post-sales investigation (PMS) plan of Lilly Korea Olumiant, which was approved for severe circular alopecia indications in adult patients over the age of 18 from the Ministry of Food and Drug Safety in March of this year, will also be changed. According to the minutes of the meeting of the Central Pharmaceutical R
1
2
3
4
5
6
7
8
9
10
>